Evidence map›Paper›PMID 36012442›Full record

ArticleInternational journal of molecular sciences2022

Full-Length Dystrophin Restoration via Targeted Exon Addition in DMD-Patient Specific iPSCs and Cardiomyocytes.

Rou Xiao, Miaojin Zhou, Peiyun Wang, Baitao Zeng, Lingqian Wu, Zhiqing Hu, Desheng Liang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. CRISPR/Cas9 systems: Delivery technologies and biomedical applications.Asian journal of pharmaceutical sciences · 2023
    Review
  5. Special Issue "Stem Cell Biology & Regenerative Medicine".International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rou XiaoCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.ORCID 0000-0003-1929-0784
Miaojin ZhouCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.ORCID 0000-0002-6636-6000
Peiyun WangCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.
Baitao ZengCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.
Lingqian WuCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.
Zhiqing HuCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.
Desheng LiangCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.
Central South University · CN

Funding

China Postdoctoral Science Foundation 2020TQ0362Fundamental Research Funds for the Central Universities of Central South University 2021zzts0087National Natural Science Foundation of China 82101957, 81902150Natural Science Foundation of Hunan Province 2021JJ40806
6 · The paper itself

Abstract

Duchenne muscular dystrophy (DMD) is the most common fatal muscle disease, with an estimated incidence of 1/3500-1/5000 male births, and it is associated with mutations in the X-linked

Indexed as

Induced Pluripotent Stem CellsMuscular Dystrophy, DuchenneDystrophinExonsHumansMaleMyocytes, CardiacDystrophincardiomyocytesDuchenne muscular dystrophyfull-length dystrophininduced pluripotent stem cellstargeted exon addition

Identifiers

PMID36012442
PMCPMC9409156
OpenAlexW4292181386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.